Genomic prognostic models in early-stage lung cancer

Clinical Lung Cancer

Volumn 10, Issue 3, 2009, Pages 151-157

  Kratz, Johannes R ^a   Jablons, David M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Microarray based molecular profiles; Quantitative polymerase chain reaction; Risk stratification

Indexed keywords

DNA; MICRORNA;

CANCER RISK; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; GENETICS; LUNG TUMOR; MORTALITY; PATHOLOGY;

GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 67649414615     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.021     Document Type: Review

References (78)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122:1037-57.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-7.
4. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706-14. (Pubitemid 47357522)
5. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379-92.
6. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172:523-9.
7. Pfannschmidt J, Muley T, Bulzebruck H, et al. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007; 55:371-7.
8. Fang D, Zhang D, Huang G, et al. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1, 905 cases. Ann Thorac Surg 2001; 72:1155-9.
9. Battafarano RJ, Piccirillo JF, Meyers Bf, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002; 123:280-7. (Pubitemid 34127115)
10. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60:615-22, discussion 22-3.
11. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-60.
12. Betticher DC. Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift. Lung Cancer 2005; 50S2:S9-S16.
13. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713-21.
14. Le Chevalier T, Arriagada R, Pignon JP, et al. Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer? Lancet Oncol 2005; 6:182-4.
15. Tsuboi M, Ohira T, Saji H, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007; 13:73-7.
16. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-97. (Pubitemid 41007845)
17. El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg 2006; 82:408-15 discussion 15-6.
18. Keenan RJ, Landreneau RJ, Maley RH, Jr, et al. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg 2004; 78:228-33 discussion 28-33.
19. Koike T, Yamato Y, Yoshiya K, et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg 2003; 125:924-8. (Pubitemid 36457515)
20. Nakamura H, Kawasaki N, Taguchi M, et al. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. Br J Cancer 2005; 92:1033-7.
21. Okada M, Koike T, Higashiyama M, et al. Radical sublobar resection for smallsized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg 2006; 132:769-75.
22. D'amico TA, Massey M, Herndon JE II, et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999; 117:736-43.
23. Harpole DH, Jr, Herndon JE II, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55:51-6.
24. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003; 100:13537-42.
25. D'amico TA. Molecular biologic staging of lung cancer. Ann Thorac Surg 2008; 85:S737-42.
26. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
27. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454:436-44.
28. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92.
29. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008; 452:553-63.
30. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270:467-70.
31. Lashkari DA, DeRisi JL, McCusker JH, et al. Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc Natl Acad Sci U S A 1997; 94:13057-62.
32. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790-5.
33. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001; 98:13784-9.
34. Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001; 159:1231-8.
35. Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003; 9:4695-704.
36. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002; 62:4963-7.
37. McDoniels-Silvers AL, Stoner GD, Lubet RA, et al. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 2002; 4:141-50.
38. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-24.
39. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002; 62:3244-50.
40. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355:570-80. (Pubitemid 44200650)
41. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006; 66:7466-72.
42. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002; 62:3005-8.
43. Borczuk AC, Shah L, Pearson GD, et al. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004; 170:167-74.
44. Gordon GJ, Richards WG, Sugarbaker DJ, et al. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 2003; 12:905-10.
45. Inamura K, Fujiwara T, Hoshida Y, et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 2005; 24:7105-13.
46. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006; 3:e467.
47. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49-54.
48. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004; 23:5360-70.
49. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9:189-98.
50. Glinksy GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from- cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115:1503-21.
51. Guo L, Ma Y, Ward R, et al. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 2006; 12:3344-54.
52. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006; 24:5079-90.
53. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13:3029-43.
54. Larson JE, Pavey SJ, Passmore LH, et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007; 28:760-6.
55. Larson JE, Pavey SJ, Passmore LH, et al. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007; 13:2946-54.
56. Petty RD, Kerr KM, Murray GI, et al. Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol 2006; 24:1729-44.
57. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14:822-7.
58. Tsao MS, Zhu C, Ding K, et al. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. J Clin Oncol 2008; 26(18 suppl):399s Abstract 7510.
59. Dh H. Jr. Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics. Thorac Surg Clin 2007; 17:167-73 viii.
60. Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med 2004; 350:1814-6.
61. Paik S, Kim CY, Song YK, et al. Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol 2005; 2:246-54.
62. Mocellin S, Provenzano M, Rossi CR, et al. DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. Ann Surg 2005; 241:16-26.
63. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007; 96:1155-8.
64. Marshall E. Getting the noise out of gene arrays. Science 2004; 306:630-1.
65. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007; 60:1205-19.
66. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, et al. A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 2004; 10:2922-7. (Pubitemid 38619666)
67. Bast RC, Jr, Hortobagyi GN. Individualized care for patients with cancer - a work in progress. N Engl J Med 2004; 351:2865-7.
68. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004; 22:811-9.
69. Chen HY, Yu SL, Chen Ch, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356:11-20.
70. Chen JJ, Peck K, Hong TM, et al. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 2001; 61:5223-30.
71. Bianchi F, Nuciforo P, Vecchi M, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117:3436-44.
72. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for earlystage non small-cell lung cancer. J Clin Oncol 2007; 25:5562-9.
73. Reed CE, Graham A, Hoda RS, et al. A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2008; 135:627-34.
74. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008; 14:4794-9.
75. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008; 14:5565-70.
76. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007; 12:631-5.
77. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen- treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-26.
78. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-34.